Bevacizumab: The phoenix of breast oncology?

Fabrice Andre; Elise Deluche; Herve Bonnefoi

doi:10.1016/S1470-2045(15)70201-9

Bevacizumab: The phoenix of breast oncology?

Fabrice Andre, Elise Deluche, Herve Bonnefoi

Résultats de recherche: Contribution à un journal › !!Comment/debate

7 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	600-601
Nombre de pages	2
journal	The Lancet Oncology
Volume	16
Numéro de publication	6
Les DOIs	https://doi.org/10.1016/S1470-2045(15)70201-9
état	Publié - 1 juin 2015

Accès au document

10.1016/S1470-2045(15)70201-9

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{9833d6ac170a48158889b5e5e248898a,

title = "Bevacizumab: The phoenix of breast oncology?",

author = "Fabrice Andre and Elise Deluche and Herve Bonnefoi",

note = "Funding Information: FA reports grants from Novartis, AstraZeneca, and Eisai, outside the submitted work. ED and HB declare no competing interests.",

year = "2015",

month = jun,

day = "1",

doi = "10.1016/S1470-2045(15)70201-9",

language = "English",

volume = "16",

pages = "600--601",

journal = "The Lancet Oncology",

issn = "1470-2045",

number = "6",

}

TY - JOUR

T1 - Bevacizumab

T2 - The phoenix of breast oncology?

AU - Andre, Fabrice

AU - Deluche, Elise

AU - Bonnefoi, Herve

N1 - Funding Information: FA reports grants from Novartis, AstraZeneca, and Eisai, outside the submitted work. ED and HB declare no competing interests.

PY - 2015/6/1

Y1 - 2015/6/1

UR - http://www.scopus.com/inward/record.url?scp=84930275346&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(15)70201-9

DO - 10.1016/S1470-2045(15)70201-9

M3 - Comment/debate

C2 - 25975636

AN - SCOPUS:84930275346

SN - 1470-2045

VL - 16

SP - 600

EP - 601

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 6

ER -